All In Biotech

NDA 050731 · Hikma

Daunorubicin Hydrochloride

Daunorubicin Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: Sep 27, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Jan 30, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,486

713 Phase 3, 266 recruiting

FAERS reports

1,648

1,634 serious, 398 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNINGS 1.Daunorubicin Hydrochloride Injection must be given into a rapidly flowing intravenous infusion. It must never be given by the intramuscular or subcutaneous route. Severe local tissue necrosis will occur if there is extravasation during administration. 2.Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg/m 2 in adults, 300 mg/m 2 in children more than 2 years of age, or 10 mg/kg in children less than 2 years of age. 3.Severe myelosuppression occurs when used in therapeutic doses; this may lead to infection or hemorrhage. 4.It is recommended that daunorubicin hydrochloride be administered only by physicians who are experienced in leukemia...

What it is approved for

From the label in effect Feb 15, 2024.

INDICATIONS AND USAGE Daunorubicin hydrochloride in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 30, 1998 Original approval · Type 3 - New Dosage Form Review
1 products under this application
  • DAUNORUBICIN HYDROCHLORIDE · DAUNORUBICIN HYDROCHLORIDE EQ 5MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Daunorubicin" as an intervention, any sponsor and status, largest first.

All 2,486 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia205
  • myelosuppression187
  • bacterial infection158
  • secondary immunodeficiency130
  • pyrexia127
  • clostridium difficile colitis115
  • off label use109
  • pancytopenia95
  • fungal infection91
  • viral infection86
  • pneumonia80
  • product use in unapproved indication80

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
200511
20066
200710
20088
20098
20107
201123
201292
201332
201417
201526
201621
201736
201898
2019108
2020111
2021127
2022203
2023212
2024204
2025123
2026159

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 695 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.